Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
CardioVascular Research Foundation, Korea
Dio
Information provided by (Responsible Party):
Seung-Jung Park, CardioVascular Research Foundation, Korea
ClinicalTrials.gov Identifier:
NCT01350778
First received: May 4, 2011
Last updated: December 11, 2016
Last verified: December 2016
  Purpose
The objective of this study is to evaluate effectiveness and safety of BioMatrix stent in the "real world" daily practice as compared with first-generation drug-eluting stents (sirolimus- or paclitaxel-eluting stents).

Condition
Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Effectiveness and Safety of BIOMATRIX in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Resource links provided by NLM:


Further study details as provided by CardioVascular Research Foundation, Korea:

Primary Outcome Measures:
  • composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) [ Time Frame: 12 months post procedure ]

Secondary Outcome Measures:
  • All Death [ Time Frame: one month ]
  • All Death [ Time Frame: 6 months ]
  • All Death [ Time Frame: yearly upto 5 years ]
  • Cardiac death [ Time Frame: one month ]
  • Cardiac death [ Time Frame: 6 months ]
  • Cardiac death [ Time Frame: yearly upto 5 years ]
  • MI [ Time Frame: one month ]
  • MI [ Time Frame: 6 months ]
  • MI [ Time Frame: yearly upto 5 years ]
  • Composite of death or MI [ Time Frame: one month ]
  • Composite of death or MI [ Time Frame: 6 months ]
  • Composite of death or MI [ Time Frame: yearly upto 5 years ]
  • Composite of cardiac death or MI [ Time Frame: one month ]
  • Composite of cardiac death or MI [ Time Frame: 6 months ]
  • Composite of cardiac death or MI [ Time Frame: yearly upto 5 years ]
  • TVR [ Time Frame: one month ]
  • TVR [ Time Frame: 6 months ]
  • TVR [ Time Frame: yearly upto 5 years ]
  • Target-lesion revascularization (TLR) [ Time Frame: one month ]
  • Target-lesion revascularization (TLR) [ Time Frame: 6 months ]
  • Target-lesion revascularization (TLR) [ Time Frame: yearly upto 5 years ]
  • Stent thrombosis (ARC criteria) [ Time Frame: one month ]
  • Stent thrombosis (ARC criteria) [ Time Frame: 6 months ]
  • Stent thrombosis (ARC criteria) [ Time Frame: yearly upto 5 years ]
  • Procedural success defined as achievement of a final diameter stenosis of <30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization [ Time Frame: 3 days in average ]
    At discharge from the index hospitalization, participants will be followed for the duration of hospital stay, an expected average of 3 days.


Estimated Enrollment: 1000
Study Start Date: May 2010
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts
Biomatrix stent
patients treated with Biomatrix stent

Detailed Description:
This study is a non-randomized, prospective, open-label registry to compare the efficacy and safety of BioMatrix stents versus first-generation drug-eluting stent (DES) in patients with coronary artery disease.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients receiving BioMatrix stents
Criteria

Inclusion Criteria:

  • Patients receiving BioMatrix stents
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

Exclusion Criteria:

  • Patients with a mixture of other DESs
  • Terminal illness with life expectancy <1 year
  • Patients with cardiogenic shock
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01350778

Locations
Korea, Republic of
24 Centers
Seoul, Korea, Republic of
Sponsors and Collaborators
Seung-Jung Park
CardioVascular Research Foundation, Korea
Dio
Investigators
Principal Investigator: Seung-Jung Park, MD, PhD Asan Medical Center
Principal Investigator: Ki Bae Seung, MD, PhD Seoul St. Mary's Hospital, Catholic University of Korea
  More Information

Responsible Party: Seung-Jung Park, MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine, CardioVascular Research Foundation, Korea
ClinicalTrials.gov Identifier: NCT01350778     History of Changes
Other Study ID Numbers: CVRF2010-03
Study First Received: May 4, 2011
Last Updated: December 11, 2016

Keywords provided by CardioVascular Research Foundation, Korea:
Coronary artery disease requiring drug eluting stents

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on April 28, 2017